We have updated our Privacy Policy and Terms of Use for Eurasia Group and its affiliates, including GZERO Media, to clarify the types of data we collect, how we collect it, how we use data and with whom we share data. By using our website you consent to our Terms and Conditions and Privacy Policy, including the transfer of your personal data to the United States from your country of residence, and our use of cookies described in our Cookie Policy.
Cancer is relentless. A diagnosis can be devastating because cancer never rests. That is why we are excited to announce the proposed acquisition of Seagen. We plan to combine our expertise with Seagen’s and deliver a powerful cancer-fighting technology called antibody–drug conjugates (ADCs) to the world. Watch to learn more about the potential of ADCs and how this proposed acquisition could help us transform the future of cancer care.